Latest Ibritumomab tiuxetan Stories
SEATTLE, Nov. 11 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc.
Having gained approval as a treatment for chronic lymphocytic leukemia earlier this year, the FDA has now extended Treanda's use to indolent B-cell non-Hodgkin's lymphoma.
Cell Therapeutics, a biopharmaceutical company, has closed the data set for preliminary analysis of the primary endpoint in the Phase III Extend trial of pixantrone for patients with relapsed diffuse large B cell non-Hodgkin's lymphoma. It has also notified Novartis that the data set has been closed.
Cephalon, a biopharmaceutical company, has announced that the FDA has approved Treanda for injection for the treatment of patients with indolent B-cell non-Hodgkin's lymphoma that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.
Genentech, Inc. (NYSE:DNA) and Biogen Idec, Inc.
Tracon Pharmaceuticals, a biopharmaceutical company developing targeted therapies for cancer and eye diseases, has appointed Bryan Leigh its new chief medical officer. Dr Leigh has previously served as chief medical officer for Paramount Biosciences.
SAN DIEGO, Oct. 21, 2008 (GLOBE NEWSWIRE) -- Tracon Pharmaceuticals, Inc., a biopharmaceutical company developing targeted therapies for cancer and eye diseases, today announced the appointment of Bryan Leigh, M.D. as Chief Medical Officer. Dr.
SEATTLE, Oct. 20 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc.
SEATTLE, Oct. 16 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc.
Genentech and Biogen Idec have announced that a global Phase III study of Rituxan in combination with fludarabine and cyclophosphamide chemotherapy met its primary endpoint of improving progression-free survival, as assessed by investigators, in patients with previously treated CD20-positive chronic lymphocytic leukemia compared to chemotherapy alone.
- Having a loud voice; vociferous; clamorous.
- Of grand or imposing sound.